Study of intervening therapy after bronchiolitis by BCG-PSN

Objective: To evaluate the value of intervening therapy with BCG-PSN following bronchiolitis and explore the mechanism.Methods:70 cases with bronchiolifis (31cases atopy+ and 39 cases atopy-) . Half of atopy+ patients and half of atopy- patients were selected randomly to form the B 1 group, the rest form the B 2 group, 39 healthy cases form the control group. The levels of IL-4, IFN- γ in cultured supematants of PBMC and IgE in blood serum were assayed in all groups. Patients in B1 group were given BCG-PSN therapy for 6 months, IL-4, IFN-γ in cultured supernatants of PBMC were measured again six months later. Recurrent wheezing times were investigated for a year. Results: Compared with control group, the levels of IL-4, IL-4/IFN-γ and serum IgE in B 1 group and B 2 group were significantly in creased in acute phase. Six month later, The levels of IL-4, IL-4/IFN-γ in B 2 group were higher than B1 group and control group. The levels of IL-4, IL-4/IFN-γand IFN-γ in B1 groups have no statistically difference with control group. The incidence of recurrent wheezing B 2 group was statistically higher than those in B1group.Conclusions: BCG-PSN is clinically effective in preventing recurrent wheezing following bronchiolitis. The intervening mechanism may be related to its regulation of TH1 and TH2 cytokines to reach their stability.